Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PHR
PHR logo

PHR Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Phreesia Inc (PHR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.320
1 Day change
-0.43%
52 Week Range
32.760
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Phreesia Inc (PHR) is not a strong buy for a beginner investor seeking long-term growth at this time. The stock is facing significant headwinds, including a disappointing fiscal 2027 revenue outlook, declining growth visibility, and negative sentiment from analysts. While the company has shown revenue growth in its latest quarter, the sharp decline in net income and EPS, coupled with bearish technical indicators and lack of strong trading signals, suggests that this is not an optimal entry point for long-term investment.

Technical Analysis

The MACD histogram is positive at 0.054, indicating some bullish momentum, but the RSI at 54.166 is neutral, offering no clear signal. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its resistance level (R1: 9.262). Overall, the technical indicators suggest a weak trend with no strong buy signal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options data shows a low put-call ratio, indicating minimal bearish sentiment, but the overall volume and open interest trends do not suggest strong bullish activity either.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • The company reported a 15.85% YoY increase in revenue for Q4 2026, showing some operational growth. Additionally, the MACD indicator suggests mild bullish momentum.

Neutral/Negative Catalysts

  • The company's fiscal 2027 revenue guidance has been reduced by 6.7%, leading to multiple analyst downgrades and price target reductions. Net income and EPS have dropped significantly YoY, and gross margin has also declined. Analysts have expressed concerns about growth visibility and the impact of regulatory policies on the company's Network Solutions unit.

Financial Performance

In Q4 2026, revenue increased by 15.85% YoY to $127.07M. However, net income dropped by 120.27% YoY to -$1.295M, and EPS fell by 118.18% YoY to $0.02. Gross margin also declined by 4.10% YoY to 60.59%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have largely downgraded the stock, with multiple firms lowering price targets significantly. The average sentiment is cautious, with concerns about growth visibility and disappointing revenue guidance. While some analysts maintain an Overweight rating, the majority have shifted to Neutral or Hold.

Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
Wall Street analysts forecast PHR stock price to rise
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.360
sliders
Low
24
Averages
29.09
High
35
Current: 9.360
sliders
Low
24
Averages
29.09
High
35
KeyBanc
Overweight
downgrade
$15 -> $12
AI Analysis
2026-04-13
Reason
KeyBanc
Price Target
$15 -> $12
AI Analysis
2026-04-13
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on Phreesia to $12 from $15 and keeps an Overweight rating on the shares. Ahead of Q1 earnings, the firm believes the setup is largely positive, with beats likely across the group. That said, KeyBanc thinks most companies will reiterate their full-year guidance given the uncertain macro. Thematically, it believes healthcare systems are continuing to see good utilization, supporting capex/ software spend, and Pharma digital advertising environment remains choppy.
Wells Fargo
Overweight
to
NULL
downgrade
$25 -> $15
2026-04-05
Reason
Wells Fargo
Price Target
$25 -> $15
2026-04-05
downgrade
Overweight
to
NULL
Reason
Wells Fargo lowered the firm's price target on Phreesia to $15 from $25 and keeps an Overweight rating on the shares. The company's fiscal 2027 revenue outlook "decelerated sharply," but appears mainly Network-driven, the analyst tells investors in a research note. Wells cites valuation compression and Phreesia's decelerated growth outlook for the target cut. The firm notes that its recent Network channel checks were constructive.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PHR
Unlock Now

People Also Watch